Maze Therapeutics, Inc.

MAZE Nasdaq SEC CIK 1842295
Follow Maze Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$48M −59.4% vs same quarter last year
EPS, diluted −$0.79 −19.7% vs same quarter last year
Operating cash flow −$32.8M −33.3% vs same quarter last year
Revenue by quarter
$0
$0
$20M
$0
$0
Q4 24 Q2 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing